Skip to content

Anxiety: all studies

Page 769 of 769: studies 7,681 to 7,685 of 7,685, newest first. Back to the anxiety overview

Research

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part VI. 3,4-methylenedioxy-methamphetamine (MDMA)

Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al. preprint

Background: After becoming notorious for its use as a party drug in the 1980s, 3,4-methylenedioxy-methampetamine (MDMA), also known by its street names “molly” and “ecstasy,” has emerged as a powerful treatment for post-traumatic stress disorder (PTSD). Areas of uncertainty: There is extensive data about the risk profile of MDMA. However, the literature is significantly biased. Animal models...

Ketamine role in the treatment of Maternal depression: effects on offspring behaviour

Research Square Taqwa B. Thanoon, Zeina A. Althanoon preprint

Abstract Maternal depression during pregnancy adversely affects offspring neurodevelopment and behaviour. Typical antidepressants like selective serotonin reuptake inhibitors have limitations due to risks of crossing the placenta. Ketamine has emerged as a promising alternative treatment. This research examined ketamine's effects on offspring of maternally stressed mice. Dams were divided into...

Psychedelic Therapy: A Primer for Primary Care Clinicians – Part II. Lysergic acid diethylamide (LSD)

Bryce D. Beutler, Kenneth Shinozuka, Burton J. Tabaac et al. preprint

Background: Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use disorder. However, LSD was banned in 1970 in part due to concerns that it could bring about or exacerbate mental illness. Its therapeutic potential remains incompletely understood.Areas of Uncertainty: While uncontrolled recreational use...

Intranasal Racemic Ketamine Maintenance Therapy for Patients with Treatment-Resistant Depression: A Naturalistic Feasibility Study

Research Square Katelyn Halpape, Raelle Pashovitz, Annabelle Wanson et al. preprint

Abstract Background Ketamine is a promising therapy for treatment-resistant depression due to its rapid onset, although benefits are often transitory, with patients needing maintenance therapy to prevent relapse. Most data supporting ketamine for treatment-resistant depression refers to the intravenous route of administration, leaving alternative routes lacking in data, especially as...

Observational cohort study of a group-based VR program to improve mental health and wellbeing in people with life-threatening illnesses

Joe Hardy, Hannes Kettner, David R. Glowacki et al. preprint

Introduction. Being diagnosed with a life-threatening illness (LTI) is often accompanied by feelings of fear, uncertainty, and loneliness that can severely impact mental health. Relatively few interventions are available to address the existential concerns of individuals facing LTI, while treatment of the underlying physical ailment typically remains the priority of the healthcare system....

DOI: 10.31234/osf.io/rs8ny (opens in new tab) Virtual reality Mental health Serious illness Digital therapeutics